---
title: "Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292545738.md"
description: "Mesoblast Limited announced it has reached its target of treating at least 300 patients in the pivotal Phase 3 MSB-DR004 trial for rexlemestrocel-L, a therapy for chronic low back pain associated with degenerative disc disease. The company aims to file for approval soon after top-line results are expected in mid-2027. Rexlemestrocel-L holds FDA Regenerative Medicine Advanced Therapy designation, and commercial manufacturing is proceeding in parallel."
datetime: "2026-07-14T00:37:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292545738.md)
  - [en](https://longbridge.com/en/news/292545738.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292545738.md)
generator: "portal-rs"
---

# Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

On July 13, 2026, Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, revealed that it has successfully treated over 300 patients in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) linked with degenerative disc disease. The goal of the trial is to validate the long-lasting pain relief achieved through a single intra-discal injection of rexlemestrocel-L as demonstrated in the prior MSB-DR003 trial. Mesoblast Limited's stocks are listed as Nasdaq:MESO and ASX:MSB.

### Related Stocks

- [MESO.US](https://longbridge.com/en/quote/MESO.US.md)
- [MSB.AU](https://longbridge.com/en/quote/MSB.AU.md)

## Related News & Research

- [Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment](https://longbridge.com/en/news/296134582.md)
- [Mesoblast completes dosing in Phase 3 rexlemestrocel-L trial for chronic low back pain](https://longbridge.com/en/news/296037778.md)
- [Mesoblast Stock Leads 3 High Growth Insider Owned ASX Shares To Watch](https://longbridge.com/en/news/296564902.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [NMRA: Advancing brain-penetrant therapies with strong early results for major CNS and metabolic diseases](https://longbridge.com/en/news/295926732.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**